Edgewise Therapeutics reports Q3 EPS (41c), consensus (40c)

Cash, cash equivalents and marketable securities were approximately $290M as of September 30. “I’m thrilled with the progress we’ve made in 2023 across our skeletal and cardiovascular programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Most recently, we started enrolling individuals in two important studies: GRAND CANYON, a global pivotal study of EDG-5506 in Becker, a disorder with no approved treatments and a Phase 1 trial of EDG-7500, our novel sarcomere modulator for HCM. The team also initiated FOX, the Phase 2 trial of EDG-5506 in boys with Duchenne who have received gene therapy and continues to rapidly enroll the Phase 2 LYNX trial in Duchenne.”